Biomea Fusion, Inc.
No enriched coverage for $BMEA in the last 7 days.
No SEC Form 4 filings for $BMEA in the last 30 days.
See all $BMEA insider activity →State Street (STT) shares fell 6.4% in pre-market trading after Q3 results showed adjusted earnings of $3.69 per share, beating estimates, but sales missed expectations at $4.004 billion. Other stocks moving lower include Biomea Fusion (BMEA), Fastenal (FAST), and Bank of America (BAC).
HC Wainwright & Co. reiterated a Buy rating and $4 price target for Biomea Fusion, implying a 217.5% upside from the Oct 13 close. The analyst cited positive clinical trial developments, including promising results from the OPAL study and encouraging Phase 1 data for BMF-650, as reasons for the rating.
Citizens reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion (BMEA) after Phase 1 data for BMF-650 showed promising results. The stock trades at $1.26, with analyst targets ranging from $4 to $10. Biomea completed enrollment in a Phase II diabetes trial, with results expected in Q1 2027. Brookline Capital Markets initiated coverage with a Buy rating and $10.00 target. The company canceled a planned public offering due to market conditions.
Recent BMEA coverage spans technology, earnings and financial news.
Disappointing early‑stage data caused a steep sell‑off.
HC Wainwright & Co. reiterated a Buy rating and $4 price target for Biomea Fusion, implying a 217.5% upside from the Oct 13 close. The analyst cited positive clinical trial developments, including promising results from the OPAL study and encouraging Phase 1 data for BMF-650, as reasons for the rating.
Positive Phase 1 results and analyst endorsement should drive buying pressure.
Shares fell sharply after the Phase 1 data, indicating market disappointment.
Positive early‑stage data may lift the stock as investors anticipate further development.
AlphAI scores every news story that mentions BMEA with an AI model for sentiment and relevance, and aggregates insider trades from Biomea Fusion, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
State Street (STT) shares fell 6.4% in pre-market trading after Q3 results showed adjusted earnings of $3.69 per share, beating estimates, but sales missed expectations at $4.004 billion. Other stocks moving lower include Biomea Fusion (BMEA), Fastenal (FAST), and Bank of America (BAC).
2 min readHC Wainwright & Co. reiterated a Buy rating and $4 price target for Biomea Fusion, implying a 217.5% upside from the Oct 13 close. The analyst cited positive clinical trial developments, including promising results from the OPAL study and encouraging Phase 1 data for BMF-650, as reasons for the rating.
1 min readCitizens reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion (BMEA) after Phase 1 data for BMF-650 showed promising results. The stock trades at $1.26, with analyst targets ranging from $4 to $10. Biomea completed enrollment in a Phase II diabetes trial, with results expected in Q1 2027. Brookline Capital Markets initiated coverage with a Buy rating and $10.00 target. The company canceled a planned public offering due to market conditions.
2 min readBiomea Fusion (BMEA) reported Phase 1 results for BMF-650, its oral GLP-1 receptor agonist for obesity. The study showed weight reduction of 1.5% to 6.1% across cohorts, with mild to moderate side effects. The company plans further studies and seeks partnerships. BMEA shares fell 28.71% overnight.
2 min readBiomea Fusion, Inc. (BMEA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 GLP-131 Phase 1 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants Week 4 Topline Results October 13, 2026 Legal Disclaimer & Forward-looking Statements Certain statements in this presentation and the accompanying oral commentary are forward
2 min readBiomea Fusion (BMEA) shares rose 6.44% to $1.44 premarket ahead of Phase I data release for obesity drug BMF-650. The trial evaluates safety, tolerability, and weight reduction in overweight/obese participants. The company expects cash runway into Q2 2027. BMEA has traded between $0.87 and $2.23 in the past year.
2 min readBrookline Capital initiated coverage on Biomea Fusion (BMEA) with a Buy rating and $10 target, citing undervaluation and strong balance sheet. The company is developing icovamenib for diabetes and BMF-650 for obesity. Two Phase 2 trials for icovamenib in type 2 diabetes are ongoing, with topline results expected in Q1 2027. H.C. Wainwright and Citizens also reiterated Buy ratings with $4 and $7 targets, respectively. Biomea canceled a planned public offering due to unfavorable market conditions.
2 min readBiomea Fusion Inc. (BMEA) shares fell 10.77% due to negative sentiment around its clinical trial outlook and a terminated equity offering. The company has no revenue, a net loss of $8.3M, and $35.2M in cash. Analysts note high dilution risk and a bearish trend, with resistance at $1.50 and support at $1.20.
2 min readBiomea Fusion Inc (BMEA) shares rose 1.2% premarket after canceling a public offering due to unfavorable market conditions. The company, which develops therapies for diabetes and obesity, cited terms unfavorable to shareholders for the cancellation. No securities were sold as part of the offering.
2 min readWorthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.
2 min read
